Goldman Sachs Group Inc. Has $3.92 Million Stock Position in Ginkgo Bioworks Holdings, Inc. $DNA

Key Points

• Goldman Sachs Group Inc. increased its stake in Ginkgo Bioworks by 25.4% in Q1, now owning 686,767 shares valued at approximately $3.9 million.
• Wall Street analysts maintain a **consensus rating of "Hold"** on Ginkgo Bioworks, with a target price averaging $9.50, despite mixed ratings from various firms.
• Ginkgo Bioworks reported earnings of ($1.10) per share, beating expectations, with revenue of $49.6 million for the last quarter.

Goldman Sachs Group Inc. raised its holdings in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA - Free Report) by 25.4% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 686,767 shares of the company's stock after acquiring an additional 139,126 shares during the period. Goldman Sachs Group Inc. owned approximately 1.17% of Ginkgo Bioworks worth $3,915,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. US Bancorp DE increased its position in shares of Ginkgo Bioworks by 43.5% in the 1st quarter. US Bancorp DE now owns 6,302 shares of the company's stock valued at $36,000 after buying an additional 1,911 shares in the last quarter. Bank of New York Mellon Corp increased its position in shares of Ginkgo Bioworks by 14.4% in the 1st quarter. Bank of New York Mellon Corp now owns 26,392 shares of the company's stock valued at $150,000 after buying an additional 3,331 shares in the last quarter. Prescott Group Capital Management L.L.C. increased its position in shares of Ginkgo Bioworks by 1.1% in the 1st quarter. Prescott Group Capital Management L.L.C. now owns 365,717 shares of the company's stock valued at $2,085,000 after buying an additional 3,967 shares in the last quarter. Green Alpha Advisors LLC increased its position in shares of Ginkgo Bioworks by 31.7% in the 1st quarter. Green Alpha Advisors LLC now owns 18,470 shares of the company's stock valued at $105,000 after buying an additional 4,449 shares in the last quarter. Finally, OMERS ADMINISTRATION Corp increased its position in shares of Ginkgo Bioworks by 14.1% in the 1st quarter. OMERS ADMINISTRATION Corp now owns 39,700 shares of the company's stock valued at $226,000 after buying an additional 4,900 shares in the last quarter. Institutional investors own 78.63% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on DNA. BTIG Research upped their price objective on shares of Ginkgo Bioworks from $6.00 to $9.00 and gave the company a "sell" rating in a research report on Monday, August 25th. Wall Street Zen upgraded Ginkgo Bioworks from a "sell" rating to a "hold" rating in a report on Saturday, August 30th. Finally, Cowen reiterated a "buy" rating on shares of Ginkgo Bioworks in a report on Friday, August 8th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Ginkgo Bioworks currently has an average rating of "Hold" and a consensus price target of $9.00.

Ginkgo Bioworks Trading Down 0.9%

Shares of Ginkgo Bioworks stock traded down $0.10 during trading hours on Friday, reaching $11.32. 1,548,571 shares of the company's stock were exchanged, compared to its average volume of 1,525,026. The company has a 50 day moving average of $12.01 and a two-hundred day moving average of $9.36. Ginkgo Bioworks Holdings, Inc. has a fifty-two week low of $5.00 and a fifty-two week high of $16.85. The stock has a market cap of $670.14 million, a P/E ratio of -1.93 and a beta of 1.50.

Ginkgo Bioworks (NYSE:DNA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($1.10) EPS for the quarter, topping analysts' consensus estimates of ($1.44) by $0.34. Ginkgo Bioworks had a negative net margin of 136.56% and a negative return on equity of 43.25%. The company had revenue of $49.60 million during the quarter, compared to the consensus estimate of $41.60 million. Ginkgo Bioworks has set its FY 2025 guidance at EPS. As a group, analysts expect that Ginkgo Bioworks Holdings, Inc. will post -10.02 earnings per share for the current fiscal year.

Ginkgo Bioworks Company Profile

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.